Page 67 - Read Online

Kawakibi et al. Plast Aesthet Res 2023;10:48 https://dx.doi.org/10.20517/2347-9264.2022.120 Page 7 of 9

REFERENCES
1. Cutolo M, Soldano S, Smith V. Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Rev Clin
Immunol 2019;15:753-64. DOI PubMed
2. Marsol I. Update on the classification and treatment of localized scleroderma. Actas Dermosifiliogr 2013;104:654-66. DOI PubMed
3. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of
rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747-55. DOI
4. Czirják L, Foeldvari I, Müller-Ladner U. Skin involvement in systemic sclerosis. Rheumatology 2008;47 Suppl 5:v44-5. DOI
PubMed
5. Vitiello M, Abuchar A, Santana N, Dehesa L, Kerdel FA. An update on the treatment of the cutaneous manifestations of systemic
sclerosis: the dermatologist's point of view. J Clin Aesthet Dermatol 2012;5:33-43. PubMed PMC
6. Pearson DR, Werth VP, Pappas-Taffer L. Systemic sclerosis: current concepts of skin and systemic manifestations. Clin Dermatol
2018;36:459-74. DOI PubMed
7. Strong AL, Adidharma W, Brown OH, Cederna PS. Fat grafting subjectively improves facial skin elasticity and hand function of
scleroderma patients. Plast Reconstr Surg Glob Open 2021;9:e3373. DOI PubMed PMC
8. Wetterau M, Szpalski C, Hazen A, Warren SM. Autologous fat grafting and facial reconstruction. J Craniofac Surg 2012;23:315-8.
DOI PubMed
9. Strong AL, Cederna PS, Rubin JP, Coleman SR, Levi B. The current state of fat grafting: a review of harvesting, processing, and
injection techniques. Plast Reconstr Surg 2015;136:897-912. DOI PubMed PMC
10. Choi M, Small K, Levovitz C, Lee C, Fadl A, Karp NS. The volumetric analysis of fat graft survival in breast reconstruction. Plast
Reconstr Surg 2013;131:185-91. DOI PubMed
11. Clauser LC, Tieghi R, Galiè M, Carinci F. Structural fat grafting: facial volumetric restoration in complex reconstructive surgery. J
Craniofac Surg 2011;22:1695-701. DOI PubMed
12. Coleman SR. Structural fat grafting: more than a permanent filler. Plast Reconstr Surg 2006;118:108S-20S. DOI PubMed
13. Coleman SR. Structural fat grafts: the ideal filler? Clin Plast Surg 2001;28:111-9. DOI PubMed
14. Gir P, Brown SA, Oni G, Kashefi N, Mojallal A, Rohrich RJ. Fat grafting: evidence-based review on autologous fat harvesting,
processing, reinjection, and storage. Plast Reconstr Surg 2012;130:249-58. DOI PubMed
15. Kaufman MR, Miller TA, Huang C, et al. Autologous fat transfer for facial recontouring: is there science behind the art? Plast
Reconstr Surg 2007;119:2287-96. DOI
16. Han S, Sun HM, Hwang KC, Kim SW. Adipose-derived stromal vascular fraction cells: update on clinical utility and efficacy. Crit Rev
Eukaryot Gene Expr 2015;25:145-52. DOI
17. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282:1145-
7. DOI
18. Rosendahl AH, Schönborn K, Krieg T. Pathophysiology of systemic sclerosis (scleroderma). Kaohsiung J Med Sci 2022;38:187-95.
DOI PubMed
19. Strong AL, Rubin JP, Kozlow JH, Cederna PS. Fat grafting for the treatment of scleroderma. Plast Reconstr Surg 2019;144:1498-507.
DOI PubMed
20. Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis.
Quantification, subtyping, and clinical correlations. Arthritis Rheum 1984;27:645-53. DOI PubMed
21. Fleischmajer R. Skin capillary changes in early systemic scleroderma: electron microscopy and "in vitro" autoradiography with
tritiated thymidine. Arch Dermatol 1976;112:1553-7. DOI PubMed
22. Kahaleh B. Vascular disease in scleroderma: mechanisms of vascular injury. Rheum Dis Clin North Am 2008;34:57-71; vi. DOI
PubMed
23. Diot E, Lesire V, Guilmot JL, et al. Systemic sclerosis and occupational risk factors: a case-control study. Occup Environ Med
2002;59:545-9. DOI PubMed PMC
24. Khalil N, Bereznay O, Sporn M, Greenberg AH. Macrophage production of transforming growth factor beta and fibroblast collagen
synthesis in chronic pulmonary inflammation. J Exp Med 1989;170:727-37. DOI PubMed PMC
25. Gilbane AJ, Denton CP, Holmes AM. Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis Res Ther
2013;15:215. DOI PubMed PMC
26. Jelaska A, Korn JH. Role of apoptosis and transforming growth factor β1 in fibroblast selection and activation in systemic sclerosis.
Arthritis & Rheumatism 2000;43:2230-9. DOI
27. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am J
Pathol 2007;170:1807-16. DOI PubMed PMC
28. Hinz B, Lagares D. Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases. Nat Rev Rheumatol 2020;16:11-31. DOI
PubMed PMC
29. Santiago B, Galindo M, Rivero M, Pablos JL. Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal
fibroblasts. Arthritis & Rheumatism 2001;44:1667-76. DOI
30. Stummvoll GH. Current treatment options in systemic Sclerosis (Scleroderma). Acta Med Austriaca 2002;29:14-9. DOI PubMed
31. Ceccarelli S, Pontecorvi P, Anastasiadou E, Napoli C, Marchese C. Immunomodulatory effect of adipose-derived stem cells: the